{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:25:35Z","timestamp":1761841535785},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Topical bimatoprost is a topical prostaglandin analog originally used to treat glaucoma and more recently used to cosmetically induce hypertrichosis of the eyelashes. Iris pigmentation change has been noted in the treatment of glaucoma but has not been assessed with the cosmetic periorbital application of bimatoprost.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate for iris pigmentation change with the long-term cosmetic use of topical bimatoprost.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>A retrospective chart review in a cosmetic dermatology practice of women (<jats:italic toggle=\"yes\">N<\/jats:italic> = 50) who consistently purchased topical bimatoprost over an average of 4.59 years was compared with that of age-matched non\u2013bimatoprost patients (<jats:italic toggle=\"yes\">N<\/jats:italic> = 50). A blinded evaluator assessed each patient for iris pigmentary change.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>No iris pigmentation change was noted with the cutaneous application of bimatoprost.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The cutaneous application of bimatoprost appears to be safe with minimal risk for iris pigmentation change.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000001208","type":"journal-article","created":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T18:11:42Z","timestamp":1495908702000},"page":"1431-1433","source":"Crossref","is-referenced-by-count":5,"title":["Retrospective Evaluation of Topical Bimatoprost and Iris Pigmentation Change"],"prefix":"10.1097","volume":"43","author":[{"given":"Lisa A.","family":"Zaleski-Larsen","sequence":"first","affiliation":[{"name":"West Dermatology, San Diego, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine H.","family":"Ruth","sequence":"additional","affiliation":[{"name":"Naval Medical Center San Diego, San Diego, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina G.","family":"Fabi","sequence":"additional","affiliation":[{"name":"Cosmetic Laser Dermatology, San Diego, California;"},{"name":"Department of Dermatology, University of California, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1473-2165.2010.00487.x","article-title":"Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement","volume":"9","author":"Woodward","year":"2010","journal-title":"J Cosmet Derm"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/DSS.0000000000000755","article-title":"Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol Surg"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1090820X12455659","article-title":"Topical bimatoprost 0.03% and iatrogenic eyelid and orbital lipodystrophy","volume":"32","author":"Sira","year":"2012","journal-title":"Aesthet Surg J"},{"key":"R4-20230814","first-page":"472","article-title":"Bimatoprost-induced chemical blepharoplasty","volume":"14","author":"Sarnoff","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/0976-500X.136110","article-title":"Hirsutism following the use of bimatoprost for glaucoma","volume":"5","author":"Kaliaperumal","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/OPTH.S55754","article-title":"Periorbital muscle atrophy associated with topical bimatoprost therapy","volume":"29","author":"Wang","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R7-20230814","first-page":"70","article-title":"PAP: New concerns for prostaglandin use","volume":"19","author":"Berke","year":"2012","journal-title":"Rev Ophthalmol"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/01.opx.0000141791.16683.4a","article-title":"Deepening of lid sulcus from topical bimatoprost therapy","volume":"81","author":"Peplinski","year":"2001","journal-title":"Optom Vis Sci"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/OPX.0b013e3182231202","article-title":"Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost","volume":"88","author":"Nakakura","year":"2011","journal-title":"Optom Vis Sci"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ceo.12163","article-title":"Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost, and travoprost","volume":"42","author":"Kucukevciloglu","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"issue":"Suppl 1","key":"R11-20230814","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S0039-6257(02)00292-8","article-title":"Mechanism and clinical significance of prostaglandin-induced iris pigmentation","volume":"47","author":"Stjernschantz","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/OPTH.S27489","article-title":"Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension","volume":"6","author":"Inoue","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/15569521003796860","article-title":"Recovery of orbital fat pad prolapses and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature","volume":"29","author":"Aydin","year":"2010","journal-title":"Cutan Ocul Toxicol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201712000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:07:38Z","timestamp":1692040058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201712000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001208","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}